Autopsy report · NCT03878927

CPX-351+GO in Subjects 55 Years Old, or Older, With AML

“Dose limiting toxicities.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 3 years before it stopped.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Weill Medical College of Cornell University

Sponsor type

University, hospital or other

Conditions

Acute Myeloid Leukemia

Interventions

CPX-351; Gemtuzumab Ozogamicin

Participants

11

Sites

1

Countries

United States

Trials that died the same way

• A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
  “Dose limiting toxicity at the lowest planned dose level.” (91% match in meaning)
• A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
  “Terminated due to dose limiting toxicity” (71% match in meaning)
• A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
  “Extreme toxicity” (70% match in meaning)
• LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma
  “toxicity” (69% match in meaning)
• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
  “The Sponsor terminated the study due to early dose-limiting toxicities.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.